Business
Hemostemix Welcomes Shaune Harding, OStJ, RN as Director of Patient Care & Clinical Operations
Calgary, Alberta--(Newsfile Corp. - December 4, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF...
About this update from Hemostemix Inc
[{"type":"text","content":"Hemostemix Welcomes Shaune Harding, OStJ, RN as Director of Patient Care & Clinical OperationsCalgary, Alberta--(Newsfile Corp. - December 4, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) (\"Hemostemix\" or the \"Company\"), a leader in autologous stem cell therapeutics for ischemic diseases, is pleased to announce the appointment of Shaune Harding, OStJ, RN non-practicing, as Director of Patient Care & Clinical Operations. In this senior clinical role, Ms. Harding will oversee:On-boarding of all new patients entering Hemostemix treatment programs;Comprehensive medical records review and HIPAA-compliant transfer of patient records to the treating physician team;Patient health-journey mapping, from initial assessment through treatment and multi-year follow-up;Continuous patient data monitoring, including heart rate, activity, exercise, and sleep metrics captured through approved wearable devices such as Fitbit Sense 2;Monthly follow-up meetings to support goal setting, healthcare journey adherence, and improvements in functional status;Adverse event monitoring, documentation, and reporting, including:Real-time tracking of patient-reported issues;Immediate escalation protocols to the treating physician;Formal reporting to Hemostemix's clinical operations team and regulators.Ensuring compliance with regulatory, clinical, and safety obligations.Ms. Harding brings more than three decades of patient-hands-on clinical and management experience to her role, which will be leveraged it to advance Hemostemix's personalized care experience in The Bahamas, Florida, and Canada. This integrated role strengthens Hemostemix's hands-on, patient-centric healthcare model. It ensures long-term continuity of care for all who are treated with VesCell. Equally important, it enables patient data capture, which will be used to advance regulatory approval of ACP-01.\"I've known Shaune since 1967,\" said Thomas Smeenk, President & CEO of Hemostemix. \"Shaune has always been one of the best-hearted friends anyone could have. Hemostemix's patients are going to love working with her, as she will help them get assessed, onboard, treated, and followed-up monthly. Shaune is the perfect person to guide patients throughout their health journey, and I'm thrilled to welcome her to head our patient care team,\" Smeenk said.ABOUT HEMOSTEMIX He...